{"id":1196,"date":"2008-10-01T12:00:00","date_gmt":"2008-10-01T10:00:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2008\/medikamente-fuer-seltene-krankheiten-orphan-drugs"},"modified":"2022-03-17T14:11:31","modified_gmt":"2022-03-17T13:11:31","slug":"medikamente-fuer-seltene-krankheiten-orphan-drugs","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2008\/medikamente-fuer-seltene-krankheiten-orphan-drugs","title":{"rendered":"Medikamente f\u00fcr seltene Krankheiten (Orphan drugs)"},"content":{"rendered":"<p>Unter \u201eOrphan Medicinal Products\u201d (OMP) bzw. \u201dOrphan drugs\u201d versteht man Arzneimittel, die zur Behandlung seltener Krankheiten eingesetzt werden. Als selten gilt innerhalb der EU eine Krankheit, wenn sie nicht mehr als f\u00fcnf pro 10 000 EU-Einwohner betrifft. Durch Anwendung der Definition auf B\u00fcrger der EU k\u00f6nnen auch weltweit h\u00e4ufige Erkrankungen, wie z.B. Tropenkrankheiten, f\u00fcr die [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Unter \u201eOrphan Medicinal Products\u201d (OMP) bzw. \u201dOrphan drugs\u201d versteht man Arzneimittel, die zur Behandlung seltener Krankheiten eingesetzt werden. Als selten gilt innerhalb der EU eine Krankheit, wenn sie nicht mehr als f\u00fcnf pro 10 000 EU-Einwohner betrifft. Durch Anwendung der Definition auf B\u00fcrger der EU k\u00f6nnen auch weltweit h\u00e4ufige Erkrankungen, wie z.B. Tropenkrankheiten, f\u00fcr die [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[189,2944,2938,2934,2936,1809,2945,2932,2939,2943,324,1828,1859,2935,458,188,1355,1360,2803,2933,2942,2941,2940,2946,2937,937,938,2949,190,435,2950,2953,2954,325,502,2958,2800,431,976,2948,2947,1136,2955,1177,2805,2956,2957,2952,1137,2951,2619,514,754,806,2927,2926,2929,936,2928,2930,1074,803,802,2931,1350],"class_list":["post-1196","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-2-chlordesoxyadenosin","tag-5-aminolaevulinsaeure","tag-agalsidase","tag-akute-lymphoblastische-leukaemie","tag-ambrisentan","tag-anagrelid","tag-anthrazyklin-extravasation","tag-arsentrioxid","tag-betain","tag-blockbuster","tag-blutdruck","tag-bosentan","tag-celecoxib","tag-chronische-eosinophile-leukaemie","tag-chronische-myeloische-leukaemie","tag-cladribin","tag-cox-2-hemmer","tag-coxibe","tag-dasatinib","tag-deferasirox","tag-dermatofibrosarcoma-protuberans","tag-dexrazoxan","tag-ductus-arteriosus","tag-eculizumab","tag-eisenueberladung","tag-gastrointestinale-stromatumoren","tag-gist","tag-gliome","tag-haarzell-leukaemie","tag-hepatozellulaeres-karzinom","tag-homozystinurie","tag-hunter-syndrom","tag-hypereosinophiles-syndrom","tag-hypertonie","tag-ibuprofen","tag-idursulfase","tag-iloprost","tag-leberzellkarzinom","tag-lenalidomid","tag-m-fabry","tag-mukopolysaccharidose-typ-ii","tag-multiples-myelom","tag-myelodysplastische-myeloproliferative-erkrankungen","tag-nierenzellkarzinom","tag-nilotinib","tag-orphan-drugs","tag-orphan-arzneimittel","tag-paroxysmale-naechtliche-haemoglobinurie","tag-plasmozytom","tag-polyposis","tag-promyelozytenleukaemie","tag-pulmonale-hypertonie","tag-schmerzen","tag-sildenafil","tag-sitaxentan-na","tag-sklerodermie","tag-sorafenib","tag-sunitinib","tag-systemische-sklerose","tag-temsirolimus","tag-thrombozythaemie","tag-tyrosinkinase-hemmer","tag-tyrosinkinase-inhibitoren","tag-ziconotid","tag-zyklooxygenase-2-hemmer"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1196","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1196"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1196\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1196"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1196"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1196"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}